Two new studies have found some new benefits of using metformin.
One study of more than 1,400 people with metabolic syndrome (MetS) found that the use of 1700 mg/d of metformin prevented the development of Type 2 diabetes (T2D). The incidence of T2D was found to be 80% lower in those taking metformin and 92% lower amongst those using metformin and adopting a Mediterranean diet.
The second study found that patients with T2D on metformin had a lower risk for all-cause dementia than those not on metformin, with the protective effect being particularly evident in patients with nonspecified diabetes. Here, researchers conducted an updated meta-analysis of published literature to investigate the effect of metformin therapy on dementia risk in patients with T2D. They found that metformin use was linked to a lower incidence of dementia in 24 comparisons from 20 studies and that Metformin use was associated with a decreased risk for dementia in patients with nonspecified T2D in 19 comparisons.
To find out more about the first study, CLICK HERE.
To find out more about the first study, CLICK HERE.
